Lenvatinib Exhibits Potent Anti-tumor Activity and Favorable Safety Profile in a Colorectal Cancer Xenograft Model

Key Points

• This research aims to evaluate the anti-tumor effects and safety profile of lenvatinib in colorectal cancer models.
• Conducted a xenograft model of colorectal cancer (CRC).
• Administered lenvatinib to assess anti-tumor activity and toxicity.
• Analyzed the involvement of the ERK pathway and apoptosis mechanisms.
• Lenvatinib showed significant anti-tumor activity against CRC.
• Minimal systemic toxicity was observed during treatment.
• Mechanistic studies indicated ERK pathway inactivation and induction of caspase-dependent apoptosis.